SLC5A2 and hydrops fetalis: The antidiabetic drug empagliflozin, which inhibits the sodium-dependent glucose cotransporter 2 (SGLT2) in the kidney, has been shown to reduce cardiovascular mortality, all-cause mortality, and hospitalization rates for heart failure (HF) in patients at high cardiovascular risk and type 2 diabetes [1].